Guarini Kathryn sold $320K of REGN

Guarini Kathryn sold 400 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $800.00 ($0.32M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Guarini Kathryn
Published Aug 12, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The only new fact is the reported open-market sale of 400 shares at $800/share on Aug. 10, with a 10b5-1 pre-arranged plan confirmed.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and modest transaction size suggest limited incremental impact.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction holdings (603 shares) are small relative to typical institutional float, limiting signal strength.

Relevance 3/10Novelty 3/10Timing: filed after-hours on Aug. 12, covering a sale dated Aug. 10

Background

The article is an SEC Form 4 insider transaction disclosure for Regeneron Pharmaceuticals, Inc.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Regeneron director Kathryn Guarini sold 400 shares in an open-market transaction at $800/share under a 10b5-1 plan, filed Aug. 12.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 reports the sale size and price ($320,000 total) and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Minimal. Insider transaction in a single biotech name does not materially reset sector expectations.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations, so any negative read-through may be overstated.

Key entities

  • REGN

    Regeneron Pharmaceuticals, Inc., the company whose director insider sale is disclosed.

  • Kathryn Guarini

    Director of Regeneron who sold 400 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.